Episode 168: Administer Irinotecan Infusions With Confidence

<p>ONS member Rae Norrod, MS, RN, CNS, AOCN^®, oncology service line manager at Kettering Health Network in Ohio and member of the West Central Ohio ONS Chapter, joins Stephanie Jardine, BSN, RN, oncology clinical specialist at ONS, to discuss how oncology nurses can safely administer irinotecan chemotherapy and manage its associated side effects and adverse events. This episode is part of an ongoing series about outpatient oncology drug infusion. The others are linked in the episode notes.</p> <p>Music Credit: "<a href="http://www.incompetech.com/">Fireflies and Stardust</a>" by Kevin MacLeod</p> <p>Licensed under Creative Commons by Attribution 3.0</p> <p>Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at myoutcomes.ons.org by August 13, 2023. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center’s Commission on Accreditation.</p> <p><strong>Episode Notes</strong></p> <p>Check out these resources from today’s episode:</p> <ul> <li><a href= "https://courses.ons.org/diweb/gateway/init/1/f/catalog*2Fitem*2Feid*2FP426"> Complete this evaluation for free NCPD</a>.</li> <li><a href= "https://www.ons.org/acq-search?search=administer%20with%20confidence&source=Podcasts"> Previous <em>Oncology Nursing Podcast</em> episodes on outpatient oncology drug infusion</a></li> <li><a href= "https://voice.ons.org/news-and-views/the-case-of-the-pancreatic-phenomenon"> <em>ONS Voice</em> article: The Case of the Pancreatic Phenomenon</a></li> <li><a href= "https://onf.ons.org/onf/41/4/allelic-expression-phase-ii-metabolizing-enzymes-and-relationship-irinotecan-toxicity"> <em>Oncology Nursing Forum</em> article: Allelic Expression of Phase II Metabolizing Enzymes and Relationship to Irinotecan Toxicity</a></li> <li><a href= "https://www.ons.org/books/clinical-guide-antineoplastic-th